Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine

Francisco J Vizoso, Noemi Eiro, Sandra Cid, Jose Schneider, Roman Perez-Fernandez, Francisco J Vizoso, Noemi Eiro, Sandra Cid, Jose Schneider, Roman Perez-Fernandez

Abstract

Earlier research primarily attributed the effects of mesenchymal stem cell (MSC) therapies to their capacity for local engrafting and differentiating into multiple tissue types. However, recent studies have revealed that implanted cells do not survive for long, and that the benefits of MSC therapy could be due to the vast array of bioactive factors they produce, which play an important role in the regulation of key biologic processes. Secretome derivatives, such as conditioned media or exosomes, may present considerable advantages over cells for manufacturing, storage, handling, product shelf life and their potential as a ready-to-go biologic product. Nevertheless, regulatory requirements for manufacturing and quality control will be necessary to establish the safety and efficacy profile of these products. Among MSCs, human uterine cervical stem cells (hUCESCs) may be a good candidate for obtaining secretome-derived products. hUCESCs are obtained by Pap cervical smear, which is a less invasive and painful method than those used for obtaining other MSCs (for example, from bone marrow or adipose tissue). Moreover, due to easy isolation and a high proliferative rate, it is possible to obtain large amounts of hUCESCs or secretome-derived products for research and clinical use.

Keywords: adipose-derived stem cells; bone marrow mesenchymal stem cells; conditioned media; exosomes; hUCESCs; mesenchymal stem cells; uterine cervical stem cells.

Conflict of interest statement

The authors declare the following competing interests: Francisco J. Vizoso, Roman Perez-Fernandez and Noemi Eiro are co-inventors of a patent (“Human uterine cervical stem cell population and uses thereof”) owned by GiStem Research, of which all authors are shareholders. The founding sponsors had no role in the design of this review, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.

References

    1. Graf T. Differentiation plasticity of hematopoietic cells. Blood. 2002;99:3089–3101. doi: 10.1182/blood.V99.9.3089.
    1. Watt F.M., Hogan B.L. Out of eden: Stem cells and their niches. Science. 2000;287:1427–1430. doi: 10.1126/science.287.5457.1427.
    1. Docheva D., Popov C., Mutschler W., Schieker M. Human mesenchymal stem cells in contact with their environment: Surface characteristics and the integrin system. J. Cell. Mol. Med. 2007;11:21–38. doi: 10.1111/j.1582-4934.2007.00001.x.
    1. Ruster B., Gottig S., Ludwig R.J., Bistrian R., Muller S., Seifried E., Gille J., Henschler R. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood. 2006;108:3938–3944. doi: 10.1182/blood-2006-05-025098.
    1. Teo G.S., Ankrum J.A., Martinelli R., Boetto S.E., Simms K., Sciuto T.E., Dvorak A.M., Karp J.M., Carman C.V. Mesenchymal stem cells transmigrate between and directly through tumor necrosis factor-α-activated endothelial cells via both leukocyte-like and novel mechanisms. Stem Cells. 2012;30:2472–2486. doi: 10.1002/stem.1198.
    1. Jiang W., Ma A., Wang T., Han K., Liu Y., Zhang Y., Zhao X., Dong A., Du Y., Huang X., et al. Intravenous transplantation of mesenchymal stem cells improves cardiac performance after acute myocardial ischemia in female rats. Transpl. Int. 2006;19:570–580. doi: 10.1111/j.1432-2277.2006.00307.x.
    1. Deans R.J., Moseley A.B. Mesenchymal stem cells: Biology and potential clinical uses. Exp. Hematol. 2000;28:875–884. doi: 10.1016/S0301-472X(00)00482-3.
    1. Gnecchi M., Zhang Z., Ni A., Dzau V.J. Paracrine mechanisms in adult stem cell signaling and therapy. Circ. Res. 2008;103:1204–1219. doi: 10.1161/CIRCRESAHA.108.176826.
    1. Friedenstein A.J., Chailakhjan R.K., Lalykina K.S. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 1970;3:393–403. doi: 10.1111/j.1365-2184.1970.tb00347.x.
    1. De Ugarte D.A., Alfonso Z., Zuk P.A., Elbarbary A., Zhu M., Ashjian P., Benhaim P., Hedrick M.H., Fraser J.K. Differential expression of stem cell mobilization-associated molecules on multi-lineage cells from adipose tissue and bone marrow. Immunol. Lett. 2003;89:267–270. doi: 10.1016/S0165-2478(03)00108-1.
    1. Orciani M., di Primio R. Skin-derived mesenchymal stem cells: Isolation, culture, and characterization. Methods Mol. Biol. 2013;989:275–283.
    1. Hua J., Yu H., Dong W., Yang C., Gao Z., Lei A., Sun Y., Pan S., Wu Y., Dou Z. Characterization of mesenchymal stem cells (MSCs) from human fetal lung: Potential differentiation of germ cells. Tissue Cell. 2009;41:448–455. doi: 10.1016/j.tice.2009.05.004.
    1. De Bari C., Dell’Accio F., Tylzanowski P., Luyten F.P. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum. 2001;44:1928–1942. doi: 10.1002/1529-0131(200108)44:8<1928::AID-ART331>;2-P.
    1. Gronthos S., Mankani M., Brahim J., Robey P.G., Shi S. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 2000;97:13625–13630. doi: 10.1073/pnas.240309797.
    1. Delorme B., Nivet E., Gaillard J., Haupl T., Ringe J., Deveze A., Magnan J., Sohier J., Khrestchatisky M., Roman F.S., et al. The human nose harbors a niche of olfactory ectomesenchymal stem cells displaying neurogenic and osteogenic properties. Stem Cells Dev. 2010;19:853–866. doi: 10.1089/scd.2009.0267.
    1. Patki S., Kadam S., Chandra V., Bhonde R. Human breast milk is a rich source of multipotent mesenchymal stem cells. Hum. Cell. 2010;23:35–40. doi: 10.1111/j.1749-0774.2010.00083.x.
    1. Shih D.T., Lee D.C., Chen S.C., Tsai R.Y., Huang C.T., Tsai C.C., Shen E.Y., Chiu W.T. Isolation and characterization of neurogenic mesenchymal stem cells in human scalp tissue. Stem Cells. 2005;23:1012–1020. doi: 10.1634/stemcells.2004-0125.
    1. Zheng B., Cao B., Crisan M., Sun B., Li G., Logar A., Yap S., Pollett J.B., Drowley L., Cassino T., et al. Prospective identification of myogenic endothelial cells in human skeletal muscle. Nat. Biotechnol. 2007;25:1025–1034. doi: 10.1038/nbt1334.
    1. De Bari C., Dell’Accio F., Luyten F.P. Human periosteum-derived cells maintain phenotypic stability and chondrogenic potential throughout expansion regardless of donor age. Arthritis Rheum. 2001;44:85–95. doi: 10.1002/1529-0131(200101)44:1<85::AID-ANR12>;2-6.
    1. Joe A.W., Yeung S.N. Concise review: Identifying limbal stem cells: Classical concepts and new challenges. Stem Cells Transl. Med. 2014;3:318–322. doi: 10.5966/sctm.2013-0137.
    1. Villaron E.M., Almeida J., Lopez-Holgado N., Alcoceba M., Sanchez-Abarca L.I., Sanchez-Guijo F.M., Alberca M., Perez-Simon J.A., san Miguel J.F., del Canizo M.C. Mesenchymal stem cells are present in peripheral blood and can engraft after allogeneic hematopoietic stem cell transplantation. Haematologica. 2004;89:1421–1427.
    1. Ulrich D., Muralitharan R., Gargett C.E. Toward the use of endometrial and menstrual blood mesenchymal stem cells for cell-based therapies. Expert Opin. Biol. Ther. 2013;13:1387–1400. doi: 10.1517/14712598.2013.826187.
    1. Eiro N., Sendon-Lago J., Seoane S., Bermudez M.A., Lamelas M.L., Garcia-Caballero T., Schneider J., Perez-Fernandez R., Vizoso F.J. Potential therapeutic effect of the secretome from human uterine cervical stem cells against both cancer and stromal cells compared with adipose tissue stem cells. Oncotarget. 2014;5:10692–10708. doi: 10.18632/oncotarget.2530.
    1. Igura K., Zhang X., Takahashi K., Mitsuru A., Yamaguchi S., Takashi T.A. Isolation and characterization of mesenchymal progenitor cells from chorionic villi of human placenta. Cytotherapy. 2004;6:543–553. doi: 10.1080/14653240410005366-1.
    1. De Coppi P., Bartsch G., Jr., Siddiqui M.M., Xu T., Santos C.C., Perin L., Mostoslavsky G., Serre A.C., Snyder E.Y., Yoo J.J., et al. Isolation of amniotic stem cell lines with potential for therapy. Nat. Biotechnol. 2007;25:100–106. doi: 10.1038/nbt1274.
    1. Wang H.S., Hung S.C., Peng S.T., Huang C.C., Wei H.M., Guo Y.J., Fu Y.S., Lai M.C., Chen C.C. Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. Stem Cells. 2004;22:1330–1337. doi: 10.1634/stemcells.2004-0013.
    1. Bieback K., Kern S., Kluter H., Eichler H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells. 2004;22:625–634. doi: 10.1634/stemcells.22-4-625.
    1. Crisan M., Yap S., Casteilla L., Chen C.W., Corselli M., Park T.S., Andriolo G., Sun B., Zheng B., Zhang L., et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008;3:301–313. doi: 10.1016/j.stem.2008.07.003.
    1. Dominici M., le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop D., Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 2006;8:315–317. doi: 10.1080/14653240600855905.
    1. Sotiropoulou P.A., Perez S.A., Salagianni M., Baxevanis C.N., Papamichail M. Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells. 2006;24:462–471. doi: 10.1634/stemcells.2004-0331.
    1. Duggal S., Brinchmann J.E. Importance of serum source for the in vitro replicative senescence of human bone marrow derived mesenchymal stem cells. J. Cell. Physiol. 2011;226:2908–2915. doi: 10.1002/jcp.22637.
    1. Baker N., Boyette L.B., Tuan R.S. Characterization of bone marrow-derived mesenchymal stem cells in aging. Bone. 2015;70:37–47. doi: 10.1016/j.bone.2014.10.014.
    1. Muller-Ehmsen J., Whittaker P., Kloner R.A., Dow J.S., Sakoda T., Long T.I., Laird P.W., Kedes L. Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. J. Mol. Cell. Cardiol. 2002;34:107–116. doi: 10.1006/jmcc.2001.1491.
    1. Toma C., Wagner W.R., Bowry S., Schwartz A., Villanueva F. Fate of culture-expanded mesenchymal stem cells in the microvasculature: In vivo observations of cell kinetics. Circ. Res. 2009;104:398–402. doi: 10.1161/CIRCRESAHA.108.187724.
    1. Ide C., Nakai Y., Nakano N., Seo T.B., Yamada Y., Endo K., Noda T., Saito F., Suzuki Y., Fukushima M., et al. Bone marrow stromal cell transplantation for treatment of sub-acute spinal cord injury in the rat. Brain Res. 2010;1332:32–47. doi: 10.1016/j.brainres.2010.03.043.
    1. Chimenti I., Smith R.R., Li T.S., Gerstenblith G., Messina E., Giacomello A., Marban E. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ. Res. 2010;106:971–980. doi: 10.1161/CIRCRESAHA.109.210682.
    1. Timmers L., Lim S.K., Hoefer I.E., Arslan F., Lai R.C., van Oorschot A.A., Goumans M.J., Strijder C., Sze S.K., Choo A., et al. Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. Stem Cell Res. 2011;6:206–214. doi: 10.1016/j.scr.2011.01.001.
    1. Lee R.H., Pulin A.A., Seo M.J., Kota D.J., Ylostalo J., Larson B.L., Semprun-Prieto L., Delafontaine P., Prockop D.J. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009;5:54–63. doi: 10.1016/j.stem.2009.05.003.
    1. Parekkadan B., Milwid J.M. Mesenchymal stem cells as therapeutics. Annu. Rev. Biomed. Eng. 2010;12:87–117. doi: 10.1146/annurev-bioeng-070909-105309.
    1. Eggenhofer E., Benseler V., Kroemer A., Popp F.C., Geissler E.K., Schlitt H.J., Baan C.C., Dahlke M.H., Hoogduijn M.J. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front. Immunol. 2012;3:297. doi: 10.3389/fimmu.2012.00297.
    1. Toma C., Pittenger M.F., Cahill K.S., Byrne B.J., Kessler P.D. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002;105:93–98. doi: 10.1161/hc0102.101442.
    1. Song Y.S., Lee H.J., Doo S.H., Lee S.J., Lim I., Chang K.T., Kim S.U. Mesenchymal stem cells overexpressing hepatocyte growth factor (HGF) inhibit collagen deposit and improve bladder function in rat model of bladder outlet obstruction. Cell Transplant. 2012;21:1641–1650. doi: 10.3727/096368912X637488.
    1. Maguire G. Stem cell therapy without the cells. Commun. Integr. Biol. 2013;6:e26631. doi: 10.4161/cib.26631.
    1. Madrigal M., Rao K.S., Riordan N.H. A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods. J. Transl. Med. 2014;12:260. doi: 10.1186/s12967-014-0260-8.
    1. Chen L., Tredget E.E., Wu P.Y., Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS ONE. 2008;3:e1886. doi: 10.1371/journal.pone.0001886.
    1. Ciapetti G., Granchi D., Baldini N. The combined use of mesenchymal stromal cells and scaffolds for bone repair. Curr. Pharm Des. 2012;18:1796–1820. doi: 10.2174/138161212799859648.
    1. Baglio S.R., Pegtel D.M., Baldini N. Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy. Front. Physiol. 2012;3:359. doi: 10.3389/fphys.2012.00359.
    1. Beer L., Mildner M., Ankersmit H.J. Cell secretome based drug substances in regenerative medicine: When regulatory affairs meet basic science. Ann. Transl. Med. 2017;5:170. doi: 10.21037/atm.2017.03.50.
    1. Bermudez M.A., Sendon-Lago J., Eiro N., Trevino M., Gonzalez F., Yebra-Pimentel E., Giraldez M.J., Macia M., Lamelas M.L., Saa J., et al. Corneal epithelial wound healing and bactericidal effect of conditioned medium from human uterine cervical stem cells. Invest. Ophthalmol. Vis. Sci. 2015;56:983–992. doi: 10.1167/iovs.14-15859.
    1. Bermudez M.A., Sendon-Lago J., Seoane S., Eiro N., Gonzalez F., Saa J., Vizoso F., Perez-Fernandez R. Anti-inflammatory effect of conditioned medium from human uterine cervical stem cells in uveitis. Exp. Eye Res. 2016;149:84–92. doi: 10.1016/j.exer.2016.06.022.
    1. Osugi M., Katagiri W., Yoshimi R., Inukai T., Hibi H., Ueda M. Conditioned media from mesenchymal stem cells enhanced bone regeneration in rat calvarial bone defects. Tissue Eng. Part A. 2012;18:1479–1489. doi: 10.1089/ten.tea.2011.0325.
    1. Vishnubhatla I., Corteling R., Stevanato L., Hicks C., Sinden J. The development of stem cell-derived exosomes as a cell-free regenerative medicine. J. Circ. Biomark. 2014;3:2. doi: 10.5772/58597.
    1. Kim D.K., Nishida H., An S.Y., Shetty A.K., Bartosh T.J., Prockop D.J. Chromatographically isolated CD63+ CD81+ extracellular vesicles from mesenchymal stromal cells rescue cognitive impairments after TBI. Proc. Natl. Acad. Sci. USA. 2016;113:170–175. doi: 10.1073/pnas.1522297113.
    1. Justewicz D.M., Shokes J.E., Reavis B., Boyd S.A., Burnette T.B., Halberstadt C.R., Spencer T., Ludlow J.W., Bertram T.A., Jain D. Characterization of the human smooth muscle cell secretome for regenerative medicine. Tissue Eng. Part C Methods. 2012;18:797–816. doi: 10.1089/ten.tec.2012.0054.
    1. Ionescu L., Byrne R.N., van Haaften T., Vadivel A., Alphonse R.S., Rey-Parra G.J., Weissmann G., Hall A., Eaton F., Thebaud B. Stem cell conditioned medium improves acute lung injury in mice: In vivo evidence for stem cell paracrine action. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012;303:L967–L977. doi: 10.1152/ajplung.00144.2011.
    1. Timmers L., Lim S.K., Arslan F., Armstrong J.S., Hoefer I.E., Doevendans P.A., Piek J.J., El Oakley R.M., Choo A., Lee C.N., et al. Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell. Res. 2007;1:129–137. doi: 10.1016/j.scr.2008.02.002.
    1. Chang C.P., Chio C.C., Cheong C.U., Chao C.M., Cheng B.C., Lin M.T. Hypoxic preconditioning enhances the therapeutic potential of the secretome from cultured human mesenchymal stem cells in experimental traumatic brain injury. Clin. Sci. 2013;124:165–176. doi: 10.1042/CS20120226.
    1. Yang D., Wang W., Li L., Peng Y., Chen P., Huang H., Guo Y., Xia X., Wang Y., Wang H., et al. The relative contribution of paracine effect versus direct differentiation on adipose-derived stem cell transplantation mediated cardiac repair. PLoS ONE. 2013;8:e59020. doi: 10.1371/journal.pone.0059020.
    1. Sevivas N., Teixeira F.G., Portugal R., Araujo L., Carrico L.F., Ferreira N., Vieira da Silva M., Espregueira-Mendes J., Anjo S., Manadas B., et al. Mesenchymal stem cell secretome: A potential tool for the prevention of muscle degenerative changes associated with chronic rotator cuff tears. Am. J. Sports Med. 2016 doi: 10.1177/0363546516657827.
    1. Bhang S.H., Lee S., Shin J.Y., Lee T.J., Jang H.K., Kim B.S. Efficacious and clinically relevant conditioned medium of human adipose-derived stem cells for therapeutic angiogenesis. Mol. Ther. 2014;22:862–872. doi: 10.1038/mt.2013.301.
    1. Zhou B.R., Xu Y., Guo S.L., Wang Y., Zhu F., Permatasari F., Wu D., Yin Z.Q., Luo D. The effect of conditioned media of adipose-derived stem cells on wound healing after ablative fractional carbon dioxide laser resurfacing. BioMed Res. Int. 2013;2013:519126. doi: 10.1155/2013/519126.
    1. Legaki E., Roubelakis M.G., Theodoropoulos G.E., Lazaris A., Kollia A., Karamanolis G., Marinos E., Gazouli M. Therapeutic potential of secreted molecules derived from human amniotic fluid mesenchymal stem/stroma cells in a mice model of colitis. Stem Cell Rev. 2016;12:604–612. doi: 10.1007/s12015-016-9677-1.
    1. Zagoura D.S., Roubelakis M.G., Bitsika V., Trohatou O., Pappa K.I., Kapelouzou A., Antsaklis A., Anagnou N.P. Therapeutic potential of a distinct population of human amniotic fluid mesenchymal stem cells and their secreted molecules in mice with acute hepatic failure. Gut. 2012;61:894–906. doi: 10.1136/gutjnl-2011-300908.
    1. Mita T., Furukawa-Hibi Y., Takeuchi H., Hattori H., Yamada K., Hibi H., Ueda M., Yamamoto A. Conditioned medium from the stem cells of human dental pulp improves cognitive function in a mouse model of Alzheimer’s disease. Behav. Brain Res. 2015;293:189–197. doi: 10.1016/j.bbr.2015.07.043.
    1. Katagiri W., Watanabe J., Toyama N., Osugi M., Sakaguchi K., Hibi H. Clinical study of bone regeneration by conditioned medium from mesenchymal stem cells after maxillary sinus floor elevation. Implant. Dent. 2017;26:607–612. doi: 10.1097/ID.0000000000000618.
    1. Hassan Famian M., Montazer Saheb S., Montaseri A. Conditioned medium of Wharton’s jelly derived stem cells can enhance the cartilage specific genes expression by chondrocytes in monolayer and mass culture systems. Adv. Pharm. Bull. 2017;7:123–130. doi: 10.15171/apb.2017.016.
    1. Park B.S., Kim W.S., Choi J.S., Kim H.K., Won J.H., Ohkubo F., Fukuoka H. Hair growth stimulated by conditioned medium of adipose-derived stem cells is enhanced by hypoxia: Evidence of increased growth factor secretion. Biomed. Res. 2010;31:27–34. doi: 10.2220/biomedres.31.27.
    1. Jang Y.J., An S.Y., Kim J.H. Identification of MFGE8 in mesenchymal stem cell secretome as an anti-fibrotic factor in liver fibrosis. BMB Rep. 2017;50:58–59. doi: 10.5483/BMBRep.2017.50.2.012.
    1. Teixeira F.G., Carvalho M.M., Panchalingam K.M., Rodrigues A.J., Mendes-Pinheiro B., Anjo S., Manadas B., Behie L.A., Sousa N., Salgado A.J. Impact of the secretome of human mesenchymal stem cells on brain structure and animal behavior in a rat model of Parkinson’s disease. Stem Cells Transl. Med. 2017;6:634–646. doi: 10.5966/sctm.2016-0071.
    1. Rajan T.S., Giacoppo S., Diomede F., Ballerini P., Paolantonio M., Marchisio M., Piattelli A., Bramanti P., Mazzon E., Trubiani O. The secretome of periodontal ligament stem cells from MS patients protects against EAE. Sci. Rep. 2016;6:38743. doi: 10.1038/srep38743.
    1. Kim M.J., Kim Z.H., Kim S.M., Choi Y.S. Conditioned medium derived from umbilical cord mesenchymal stem cells regenerates atrophied muscles. Tissue Cell. 2016;48:533–543. doi: 10.1016/j.tice.2016.06.010.
    1. Keating A. Mesenchymal stromal cells: New directions. Cell Stem Cell. 2012;10:709–716. doi: 10.1016/j.stem.2012.05.015.
    1. Fierabracci A., del Fattore A., Muraca M., Delfino D.V. The use of mesenchymal stem cells for the treatment of autoimmunity: From animals models to human disease. Curr. Drug Targets. 2016;17:229–238. doi: 10.2174/1389450116666150722140633.
    1. Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hassan M., Uzunel M., Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439–1441. doi: 10.1016/S0140-6736(04)16104-7.
    1. English K., French A., Wood K.J. Mesenchymal stromal cells: Facilitators of successful transplantation? Cell Stem Cell. 2010;7:431–442. doi: 10.1016/j.stem.2010.09.009.
    1. Ryan J.M., Barry F.P., Murphy J.M., Mahon B.P. Mesenchymal stem cells avoid allogeneic rejection. J. Inflamm. 2005;2:8. doi: 10.1186/1476-9255-2-8.
    1. Fierabracci A., del Fattore A., Muraca M. The immunoregulatory activity of mesenchymal stem cells: ‘State of art’ and ‘future avenues’. Curr. Med. Chem. 2016;23:3014–3024. doi: 10.2174/0929867323666160627112827.
    1. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., Grisanti S., Gianni A.M. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838–3843. doi: 10.1182/blood.V99.10.3838.
    1. Liang X., Ding Y., Zhang Y., Tse H.F., Lian Q. Paracrine mechanisms of mesenchymal stem cell-based therapy: Current status and perspectives. Cell Transplant. 2014;23:1045–1059. doi: 10.3727/096368913X667709.
    1. Cantinieaux D., Quertainmont R., Blacher S., Rossi L., Wanet T., Noel A., Brook G., Schoenen J., Franzen R. Conditioned medium from bone marrow-derived mesenchymal stem cells improves recovery after spinal cord injury in rats: An original strategy to avoid cell transplantation. PLoS ONE. 2013;8:e69515. doi: 10.1371/journal.pone.0069515.
    1. See F., Seki T., Psaltis P.J., Sondermeijer H.P., Gronthos S., Zannettino A.C., Govaert K.M., Schuster M.D., Kurlansky P.A., Kelly D.J., et al. Therapeutic effects of human STRO-3-selected mesenchymal precursor cells and their soluble factors in experimental myocardial ischemia. J. Cell. Mol. Med. 2011;15:2117–2129. doi: 10.1111/j.1582-4934.2010.01241.x.
    1. Mirabella T., Cilli M., Carlone S., Cancedda R., Gentili C. Amniotic liquid derived stem cells as reservoir of secreted angiogenic factors capable of stimulating neo-arteriogenesis in an ischemic model. Biomaterials. 2011;32:3689–3699. doi: 10.1016/j.biomaterials.2011.01.071.
    1. Lee M.J., Kim J., Lee K.I., Shin J.M., Chae J.I., Chung H.M. Enhancement of wound healing by secretory factors of endothelial precursor cells derived from human embryonic stem cells. Cytotherapy. 2011;13:165–178. doi: 10.3109/14653249.2010.512632.
    1. Caplan A.I. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J. Cell. Physiol. 2007;213:341–347. doi: 10.1002/jcp.21200.
    1. Yi T., Song S.U. Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch. Pharm. Res. 2012;35:213–221. doi: 10.1007/s12272-012-0202-z.
    1. Li B., Zhang H., Zeng M., He W., Li M., Huang X., Deng D.Y., Wu J. Bone marrow mesenchymal stem cells protect alveolar macrophages from lipopolysaccharide-induced apoptosis partially by inhibiting the Wnt/β-catenin pathway. Cell Biol. Int. 2015;39:192–200. doi: 10.1002/cbin.10359.
    1. Tang Y.L., Zhao Q., Qin X., Shen L., Cheng L., Ge J., Phillips M.I. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann. Thorac. Surg. 2005;80:229–236. doi: 10.1016/j.athoracsur.2005.02.072.
    1. Ranganath S.H., Levy O., Inamdar M.S., Karp J.M. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell. 2012;10:244–258. doi: 10.1016/j.stem.2012.02.005.
    1. Salgado A.J., Reis R.L., Sousa N.J., Gimble J.M. Adipose tissue derived stem cells secretome: Soluble factors and their roles in regenerative medicine. Curr. Stem Cell Res. Ther. 2010;5:103–110. doi: 10.2174/157488810791268564.
    1. Stastna M., van Eyk J.E. Investigating the secretome: Lessons about the cells that comprise the heart. Circ. Cardiovasc. Genet. 2012;5:o8–o18. doi: 10.1161/CIRCGENETICS.111.960187.
    1. Drago D., Cossetti C., Iraci N., Gaude E., Musco G., Bachi A., Pluchino S. The stem cell secretome and its role in brain repair. Biochimie. 2013;95:2271–2285. doi: 10.1016/j.biochi.2013.06.020.
    1. Wilson S.E., Mohan R.R., Ambrosio R., Jr., Hong J., Lee J. The corneal wound healing response: Cytokine-mediated interaction of the epithelium, stroma, and inflammatory cells. Prog. Retin. Eye Res. 2001;20:625–637. doi: 10.1016/S1350-9462(01)00008-8.
    1. Lu P., Li L., Wu Y., Mukaida N., Zhang X. Essential contribution of CCL3 to alkali-induced corneal neovascularization by regulating vascular endothelial growth factor production by macrophages. Mol. Vis. 2008;14:1614–1622.
    1. Kim J., Lee J.H., Yeo S.M., Chung H.M., Chae J.I. Stem cell recruitment factors secreted from cord blood-derived stem cells that are not secreted from mature endothelial cells enhance wound healing. In Vitro Cell. Dev. Biol. Anim. 2014;50:146–154. doi: 10.1007/s11626-013-9687-0.
    1. Litwack G. Human Biochemistry and Disease. Academic Press; Cambridge, MA, USA: 2008.
    1. Ray P., Devaux Y., Stolz D.B., Yarlagadda M., Watkins S.C., Lu Y., Chen L., Yang X.F., Ray A. Inducible expression of keratinocyte growth factor (KGF) in mice inhibits lung epithelial cell death induced by hyperoxia. Proc. Natl. Acad. Sci. USA. 2003;100:6098–6103. doi: 10.1073/pnas.1031851100.
    1. Turner J.E., Morrison P.J., Wilhelm C., Wilson M., Ahlfors H., Renauld J.C., Panzer U., Helmby H., Stockinger B. IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation. J. Exp. Med. 2013;210:2951–2965. doi: 10.1084/jem.20130071.
    1. Bakondi B., Shimada I.S., Perry A., Munoz J.R., Ylostalo J., Howard A.B., Gregory C.A., Spees J.L. CD133 identifies a human bone marrow stem/progenitor cell sub-population with a repertoire of secreted factors that protect against stroke. Mol. Ther. 2009;17:1938–1947. doi: 10.1038/mt.2009.185.
    1. Cargnoni A., Ressel L., Rossi D., Poli A., Arienti D., Lombardi G., Parolini O. Conditioned medium from amniotic mesenchymal tissue cells reduces progression of bleomycin-induced lung fibrosis. Cytotherapy. 2012;14:153–161. doi: 10.3109/14653249.2011.613930.
    1. Preda M.B., Ronningen T., Burlacu A., Simionescu M., Moskaug J.O., Valen G. Remote transplantation of mesenchymal stem cells protects the heart against ischemia-reperfusion injury. Stem Cells. 2014;32:2123–2134. doi: 10.1002/stem.1687.
    1. Tang J., Wang J., Guo L., Kong X., Yang J., Zheng F., Zhang L., Huang Y. Mesenchymal stem cells modified with stromal cell-derived factor 1 α improve cardiac remodeling via paracrine activation of hepatocyte growth factor in a rat model of myocardial infarction. Mol. Cells. 2010;29:9–19. doi: 10.1007/s10059-010-0001-7.
    1. Williams A.R., Suncion V.Y., McCall F., Guerra D., Mather J., Zambrano J.P., Heldman A.W., Hare J.M. Durable scar size reduction due to allogeneic mesenchymal stem cell therapy regulates whole-chamber remodeling. J. Am. Heart Assoc. 2013;2:e000140. doi: 10.1161/JAHA.113.000140.
    1. Ratajczak J., Bronckaers A., Dillen Y., Gervois P., Vangansewinkel T., Driesen R.B., Wolfs E., Lambrichts I., Hilkens P. The neurovascular properties of dental stem cells and their importance in dental tissue engineering. Stem Cells Int. 2016;2016:9762871. doi: 10.1155/2016/9762871.
    1. Caseiro A.R., Pereira T., Ivanova G., Luis A.L., Mauricio A.C. Neuromuscular regeneration: Perspective on the application of mesenchymal stem cells and their secretion products. Stem Cells Int. 2016;2016:9756973. doi: 10.1155/2016/9756973.
    1. Luarte A., Batiz L.F., Wyneken U., Lafourcade C. Potential therapies by stem cell-derived exosomes in CNS diseases: Focusing on the neurogenic niche. Stem Cells Int. 2016;2016:5736059. doi: 10.1155/2016/5736059.
    1. De Almeida J.F., Chen P., Henry M.A., Diogenes A. Stem cells of the apical papilla regulate trigeminal neurite outgrowth and targeting through a BDNF-dependent mechanism. Tissue Eng. Part A. 2014;20:3089–3100. doi: 10.1089/ten.tea.2013.0347.
    1. Mead B., Logan A., Berry M., Leadbeater W., Scheven B.A. Paracrine-mediated neuroprotection and neuritogenesis of axotomised retinal ganglion cells by human dental pulp stem cells: Comparison with human bone marrow and adipose-derived mesenchymal stem cells. PLoS ONE. 2014;9:e109305. doi: 10.1371/journal.pone.0109305.
    1. Salgado A.J., Sousa J.C., Costa B.M., Pires A.O., Mateus-Pinheiro A., Teixeira F.G., Pinto L., Sousa N. Mesenchymal stem cells secretome as a modulator of the neurogenic niche: Basic insights and therapeutic opportunities. Front. Cell Neurosci. 2015;9:249. doi: 10.3389/fncel.2015.00249.
    1. Burlacu A., Grigorescu G., Rosca A.M., Preda M.B., Simionescu M. Factors secreted by mesenchymal stem cells and endothelial progenitor cells have complementary effects on angiogenesis in vitro. Stem Cells Dev. 2013;22:643–653. doi: 10.1089/scd.2012.0273.
    1. Hsieh J.Y., Wang H.W., Chang S.J., Liao K.H., Lee I.H., Lin W.S., Wu C.H., Lin W.Y., Cheng S.M. Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to neuroprotection, neurogenesis, and angiogenesis. PLoS ONE. 2013;8:e72604. doi: 10.1371/journal.pone.0072604.
    1. Liu G., Pareta R.A., Wu R., Shi Y., Zhou X., Liu H., Deng C., Sun X., Atala A., Opara E.C., et al. Skeletal myogenic differentiation of urine-derived stem cells and angiogenesis using microbeads loaded with growth factors. Biomaterials. 2013;34:1311–1326. doi: 10.1016/j.biomaterials.2012.10.038.
    1. Sharma A.K., Bury M.I., Fuller N.J., Marks A.J., Kollhoff D.M., Rao M.V., Hota P.V., Matoka D.J., Edassery S.L., Thaker H., et al. Cotransplantation with specific populations of spina bifida bone marrow stem/progenitor cells enhances urinary bladder regeneration. Proc. Natl. Acad. Sci. USA. 2013;110:4003–4008. doi: 10.1073/pnas.1220764110.
    1. Boomsma R.A., Geenen D.L. Mesenchymal stem cells secrete multiple cytokines that promote angiogenesis and have contrasting effects on chemotaxis and apoptosis. PLoS ONE. 2012;7:e35685. doi: 10.1371/journal.pone.0035685.
    1. Kinnaird T., Stabile E., Burnett M.S., Shou M., Lee C.W., Barr S., Fuchs S., Epstein S.E. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation. 2004;109:1543–1549. doi: 10.1161/01.CIR.0000124062.31102.57.
    1. Hung S.C., Pochampally R.R., Chen S.C., Hsu S.C., Prockop D.J. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells. 2007;25:2363–2370. doi: 10.1634/stemcells.2006-0686.
    1. Wu Y., Chen L., Scott P.G., Tredget E.E. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells. 2007;25:2648–2659. doi: 10.1634/stemcells.2007-0226.
    1. Chen X., Lin X., Zhao J., Shi W., Zhang H., Wang Y., Kan B., Du L., Wang B., Wei Y., et al. A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol. Ther. 2008;16:749–756. doi: 10.1038/mt.2008.3.
    1. Estrada R., Li N., Sarojini H., An J., Lee M.J., Wang E. Secretome from mesenchymal stem cells induces angiogenesis via Cyr61. J. Cell. Physiol. 2009;219:563–571. doi: 10.1002/jcp.21701.
    1. Di Santo S., Yang Z., Wyler von Ballmoos M., Voelzmann J., Diehm N., Baumgartner I., Kalka C. Novel cell-free strategy for therapeutic angiogenesis: In vitro generated conditioned medium can replace progenitor cell transplantation. PLoS ONE. 2009;4:e5643. doi: 10.1371/journal.pone.0005643.
    1. Yun Y.R., Won J.E., Jeon E., Lee S., Kang W., Jo H., Jang J.H., Shin U.S., Kim H.W. Fibroblast growth factors: Biology, function, and application for tissue regeneration. J. Tissue Eng. 2010;2010:218142. doi: 10.4061/2010/218142.
    1. Ho J.C., Lai W.H., Li M.F., Au K.W., Yip M.C., Wong N.L., Ng E.S., Lam F.F., Siu C.W., Tse H.F. Reversal of endothelial progenitor cell dysfunction in patients with type 2 diabetes using a conditioned medium of human embryonic stem cell-derived endothelial cells. Diabetes Metab. Res. Rev. 2012;28:462–473. doi: 10.1002/dmrr.2304.
    1. Zanotti L., Angioni R., Cali B., Soldani C., Ploia C., Moalli F., Gargesha M., D’Amico G., Elliman S., Tedeschi G., et al. Mouse mesenchymal stem cells inhibit high endothelial cell activation and lymphocyte homing to lymph nodes by releasing TIMP-1. Leukemia. 2016;30:1143–1154. doi: 10.1038/leu.2016.33.
    1. De Luca A., Gallo M., Aldinucci D., Ribatti D., Lamura L., D’Alessio A., De Filippi R., Pinto A., Normanno N. Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. J. Cell. Physiol. 2011;226:2131–2138. doi: 10.1002/jcp.22548.
    1. Wong R.S. Mesenchymal stem cells: Angels or demons? J. Biomed. Biotechnol. 2011;2011:459510. doi: 10.1155/2011/459510.
    1. Houthuijzen J.M., Daenen L.G., Roodhart J.M., Voest E.E. The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression. Br. J. Cancer. 2012;106:1901–1906. doi: 10.1038/bjc.2012.201.
    1. Attar-Schneider O., Zismanov V., Drucker L., Gottfried M. Secretome of human bone marrow mesenchymal stem cells: An emerging player in lung cancer progression and mechanisms of translation initiation. Tumor. Biol. 2016;37:4755–4765. doi: 10.1007/s13277-015-4304-3.
    1. Marcus H., Attar-Schneider O., Dabbah M., Zismanov V., Tartakover-Matalon S., Lishner M., Drucker L. Mesenchymal stem cells secretomes’ affect multiple myeloma translation initiation. Cell. Signal. 2016;28:620–630. doi: 10.1016/j.cellsig.2016.03.003.
    1. Onzi G.R., Ledur P.F., Hainzenreder L.D., Bertoni A.P., Silva A.O., Lenz G., Wink M.R. Analysis of the safety of mesenchymal stromal cells secretome for glioblastoma treatment. Cytotherapy. 2016;18:828–837. doi: 10.1016/j.jcyt.2016.03.299.
    1. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., Richardson A.L., Polyak K., Tubo R., Weinberg R.A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449:557–563. doi: 10.1038/nature06188.
    1. Muehlberg F.L., Song Y.H., Krohn A., Pinilla S.P., Droll L.H., Leng X., Seidensticker M., Ricke J., Altman A.M., Devarajan E., et al. Tissue-resident stem cells promote breast cancer growth and metastasis. Carcinogenesis. 2009;30:589–597. doi: 10.1093/carcin/bgp036.
    1. Galie M., Konstantinidou G., Peroni D., Scambi I., Marchini C., Lisi V., Krampera M., Magnani P., Merigo F., Montani M., et al. Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice. Oncogene. 2008;27:2542–2551. doi: 10.1038/sj.onc.1210920.
    1. Masuda H., Zhang D., Bartholomeusz C., Doihara H., Hortobagyi G.N., Ueno N.T. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res. Treat. 2012;136:331–345. doi: 10.1007/s10549-012-2289-9.
    1. Korkaya H., Liu S., Wicha M.S. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J. Clin. Investig. 2011;121:3804–3809. doi: 10.1172/JCI57099.
    1. Park J.K., Park S.H., So K., Bae I.H., Yoo Y.D., Um H.D. ICAM-3 enhances the migratory and invasive potential of human non-small cell lung cancer cells by inducing MMP-2 and MMP-9 via Akt and CREB. Int. J. Oncol. 2010;36:181–192. doi: 10.3892/ijo_00000489.
    1. Dethlefsen C., Hojfeldt G., Hojman P. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res. Treat. 2013;138:657–664. doi: 10.1007/s10549-013-2488-z.
    1. Won H.S., Kim Y.A., Lee J.S., Jeon E.K., An H.J., Sun D.S., Ko Y.H., Kim J.S. Soluble interleukin-6 receptor is a prognostic marker for relapse-free survival in estrogen receptor-positive breast cancer. Cancer Investig. 2013;31:516–521. doi: 10.3109/07357907.2013.826239.
    1. Rajaram M., Li J., Egeblad M., Powers R.S. System-wide analysis reveals a complex network of tumor-fibroblast interactions involved in tumorigenicity. PLoS Genet. 2013;9:e1003789. doi: 10.1371/journal.pgen.1003789.
    1. Verjans E., Noetzel E., Bektas N., Schutz A.K., Lue H., Lennartz B., Hartmann A., Dahl E., Bernhagen J. Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer. BMC Cancer. 2009;9:230. doi: 10.1186/1471-2407-9-230.
    1. Karnezis T., Shayan R., Caesar C., Roufail S., Harris N.C., Ardipradja K., Zhang Y.F., Williams S.P., Farnsworth R.H., Chai M.G., et al. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell. 2012;21:181–195. doi: 10.1016/j.ccr.2011.12.026.
    1. Pasero C., Barbarat B., Just-Landi S., Bernard A., Aurran-Schleinitz T., Rey J., Eldering E., Truneh A., Costello R.T., Olive D. A role for HVEM, but not lymphotoxin-β receptor, in LIGHT-induced tumor cell death and chemokine production. Eur. J. Immunol. 2009;39:2502–2514. doi: 10.1002/eji.200939069.
    1. Silver D.F., Hempling R.E., Piver M.S., Repasky E.A. Flt-3 ligand inhibits growth of human ovarian tumors engrafted in severe combined immunodeficient mice. Gynecol. Oncol. 2000;77:377–382. doi: 10.1006/gyno.2000.5782.
    1. Bronger H., Kraeft S., Schwarz-Boeger U., Cerny C., Stockel A., Avril S., Kiechle M., Schmitt M. Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer. Breast Cancer Res. 2012;14:R30. doi: 10.1186/bcr3115.
    1. Schneider J., Eiro N., Perez-Fernandez R., Martinez-Ordonez A., Vizoso F. Human uterine cervical stromal stem cells (hUCESCs): Why and how they exert their antitumor activity. Cancer Genom. Proteom. 2016;13:331–337.
    1. Grizzle W.E., Srivastava S., Manne U. The biology of incipient, pre-invasive or intraepithelial neoplasia. Cancer Biomark. 2010;9:21–39. doi: 10.3233/CBM-2011-0172.
    1. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432:332–337. doi: 10.1038/nature03096.
    1. Vizoso F.J., Gonzalez L.O., Corte M.D., Rodriguez J.C., Vazquez J., Lamelas M.L., Junquera S., Merino A.M., Garcia-Muniz J.L. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br. J. Cancer. 2007;96:903–911. doi: 10.1038/sj.bjc.6603666.
    1. Mao Y., Keller E.T., Garfield D.H., Shen K., Wang J. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev. 2013;32:303–315. doi: 10.1007/s10555-012-9415-3.
    1. Allavena P., Sica A., Solinas G., Porta C., Mantovani A. The inflammatory micro-environment in tumor progression: The role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol. 2008;66:1–9. doi: 10.1016/j.critrevonc.2007.07.004.
    1. Becker J.C., Andersen M.H., Schrama D., Thor Straten P. Immune-suppressive properties of the tumor microenvironment. Cancer Immunol. Immunother. 2013;62:1137–1148. doi: 10.1007/s00262-013-1434-6.
    1. Zhang Q.W., Liu L., Gong C.Y., Shi H.S., Zeng Y.H., Wang X.Z., Zhao Y.W., Wei Y.Q. Prognostic significance of tumor-associated macrophages in solid tumor: A meta-analysis of the literature. PLoS ONE. 2012;7:e50946. doi: 10.1371/journal.pone.0050946.
    1. Eiro N., Pidal I., Fernandez-Garcia B., Junquera S., Lamelas M.L., del Casar J.M., Gonzalez L.O., Lopez-Muniz A., Vizoso F.J. Impact of CD68/(CD3+ CD20) ratio at the invasive front of primary tumors on distant metastasis development in breast cancer. PLoS ONE. 2012;7:e52796. doi: 10.1371/journal.pone.0052796.
    1. Gupta N., Su X., Popov B., Lee J.W., Serikov V., Matthay M.A. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J. Immunol. 2007;179:1855–1863. doi: 10.4049/jimmunol.179.3.1855.
    1. Gonzalez-Rey E., Anderson P., Gonzalez M.A., Rico L., Buscher D., Delgado M. Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut. 2009;58:929–939. doi: 10.1136/gut.2008.168534.
    1. Nemeth K., Leelahavanichkul A., Yuen P.S., Mayer B., Parmelee A., Doi K., Robey P.G., Leelahavanichkul K., Koller B.H., Brown J.M., et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 2009;15:42–49. doi: 10.1038/nm.1905.
    1. Mei S.H., Haitsma J.J., Dos Santos C.C., Deng Y., Lai P.F., Slutsky A.S., Liles W.C., Stewart D.J. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am. J. Respir. Crit. Care Med. 2010;182:1047–1057. doi: 10.1164/rccm.201001-0010OC.
    1. Krasnodembskaya A., Song Y., Fang X., Gupta N., Serikov V., Lee J.W., Matthay M.A. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide IL-37. Stem Cells. 2010;28:2229–2238. doi: 10.1002/stem.544.
    1. Yang D., Chen Q., Hoover D.M., Staley P., Tucker K.D., Lubkowski J., Oppenheim J.J. Many chemokines including CCL20/MIP-3α display antimicrobial activity. J. Leukoc. Biol. 2003;74:448–455. doi: 10.1189/jlb.0103024.
    1. Egesten A., Eliasson M., Johansson H.M., Olin A.I., Morgelin M., Mueller A., Pease J.E., Frick I.M., Bjorck L. The CXC chemokine MIG/CXCl9 is important in innate immunity against streptococcus pyogenes. J. Infect. Dis. 2007;195:684–693. doi: 10.1086/510857.
    1. Yount N.Y., Waring A.J., Gank K.D., Welch W.H., Kupferwasser D., Yeaman M.R. Structural correlates of antimicrobial efficacy in IL-8 and related human kinocidins. Biochim. Biophys. Acta. 2007;1768:598–608. doi: 10.1016/j.bbamem.2006.11.011.
    1. Collin M., Linge H.M., Bjartell A., Giwercman A., Malm J., Egesten A. Constitutive expression of the antibacterial CXC chemokine GCP-2/CXCL6 by epithelial cells of the male reproductive tract. J. Reprod. Immunol. 2008;79:37–43. doi: 10.1016/j.jri.2008.08.003.
    1. Linge H.M., Collin M., Nordenfelt P., Morgelin M., Malmsten M., Egesten A. The human CXC chemokine granulocyte chemotactic protein 2 (GCP-2)/CXCL6 possesses membrane-disrupting properties and is antibacterial. Antimicrob. Agents Chemother. 2008;52:2599–2607. doi: 10.1128/AAC.00028-08.
    1. Vieira N.M., Zucconi E., Bueno C.R., Jr., Secco M., Suzuki M.F., Bartolini P., Vainzof M., Zatz M. Human multipotent mesenchymal stromal cells from distinct sources show different in vivo potential to differentiate into muscle cells when injected in dystrophic mice. Stem Cell Rev. 2010;6:560–566. doi: 10.1007/s12015-010-9187-5.
    1. Assoni A., Castello G., Valadares M., Beccari M., Gomes J., Pelatti M., Mitne-Neto M., Carvalho V.M., Zatz M. Different donors mesenchymal stromal cells secretomes reveal heterogeneous profile of relevance for therapeutic use. Stem Cells Dev. 2017;26:206–214. doi: 10.1089/scd.2016.0218.
    1. Nakanishi C., Nagaya N., Ohnishi S., Yamahara K., Takabatake S., Konno T., Hayashi K., Kawashiri M.A., Tsubokawa T., Yamagishi M. Gene and protein expression analysis of mesenchymal stem cells derived from rat adipose tissue and bone marrow. Circ. J. 2011;75:2260–2268. doi: 10.1253/circj.CJ-11-0246.
    1. Pires A.O., Mendes-Pinheiro B., Teixeira F.G., Anjo S.I., Ribeiro-Samy S., Gomes E.D., Serra S.C., Silva N.A., Manadas B., Sousa N., et al. Unveiling the differences of secretome of human bone marrow mesenchymal stem cells, adipose tissue-derived stem cells, and human umbilical cord perivascular cells: A proteomic analysis. Stem Cells Dev. 2016;25:1073–1083. doi: 10.1089/scd.2016.0048.
    1. Pawitan J.A. Prospect of stem cell conditioned medium in regenerative medicine. BioMed Res. Int. 2014;2014:965849. doi: 10.1155/2014/965849.
    1. Basu J., Ludlow J.W. Exosomes for repair, regeneration and rejuvenation. Expert Opin. Biol. Ther. 2016;16:489–506. doi: 10.1517/14712598.2016.1131976.
    1. Feng D., Zhao W.L., Ye Y.Y., Bai X.C., Liu R.Q., Chang L.F., Zhou Q., Sui S.F. Cellular internalization of exosomes occurs through phagocytosis. Traffic. 2010;11:675–687. doi: 10.1111/j.1600-0854.2010.01041.x.
    1. Svensson K.J., Christianson H.C., Wittrup A., Bourseau-Guilmain E., Lindqvist E., Svensson L.M., Morgelin M., Belting M. Exosome uptake depends on ERK1/2-heat shock protein 27 signaling and lipid Raft-mediated endocytosis negatively regulated by caveolin-1. J. Biol. Chem. 2013;288:17713–17724. doi: 10.1074/jbc.M112.445403.
    1. Lee Y., El Andaloussi S., Wood M.J. Exosomes and microvesicles: Extracellular vesicles for genetic information transfer and gene therapy. Hum. Mol. Genet. 2012;21:R125–R134. doi: 10.1093/hmg/dds317.
    1. Lamichhane T.N., Sokic S., Schardt J.S., Raiker R.S., Lin J.W., Jay S.M. Emerging roles for extracellular vesicles in tissue engineering and regenerative medicine. Tissue Eng. Part B Rev. 2015;21:45–54. doi: 10.1089/ten.teb.2014.0300.
    1. Gyorgy B., Hung M.E., Breakefield X.O., Leonard J.N. Therapeutic applications of extracellular vesicles: Clinical promise and open questions. Annu. Rev. Pharmacol. Toxicol. 2015;55:439–464. doi: 10.1146/annurev-pharmtox-010814-124630.
    1. Kilpinen L., Impola U., Sankkila L., Ritamo I., Aatonen M., Kilpinen S., Tuimala J., Valmu L., Levijoki J., Finckenberg P., et al. Extracellular membrane vesicles from umbilical cord blood-derived MSC protect against ischemic acute kidney injury, a feature that is lost after inflammatory conditioning. J. Extracell. Vesicles. 2013;2 doi: 10.3402/jev.v2i0.21927.
    1. Lai R.C., Arslan F., Lee M.M., Sze N.S., Choo A., Chen T.S., Salto-Tellez M., Timmers L., Lee C.N., El Oakley R.M., et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010;4:214–222. doi: 10.1016/j.scr.2009.12.003.
    1. Gatti S., Bruno S., Deregibus M.C., Sordi A., Cantaluppi V., Tetta C., Camussi G. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol. Dial. Transplant. 2011;26:1474–1483. doi: 10.1093/ndt/gfr015.
    1. Tang X.-D., Shi L., Monsel A., Li X.-Y., Zhu H.-L., Zhu Y.-G., Qu J.-M. Mesenchymal stem cell microvesicles attenuate acute lung injury in mice partly mediated by Ang-1 mRNA. Stem Cells. 2017;35:1849–1859. doi: 10.1002/stem.2619.
    1. Zhang B., Shi Y., Gong A., Pan Z., Shi H., Yang H., Fu H., Yan Y., Zhang X., Wang M., et al. HucMSC exosome-delivered 14-3-3ζ orchestrates self-control of the Wnt response via modulation of YAP during cutaneous regeneration. Stem Cells. 2016;34:2485–2500. doi: 10.1002/stem.2432.
    1. Yin G., Hu G., Wan R., Yu G., Cang X., Xiong J., Ni J., Hu Y., Xing M., Fan Y., et al. Role of microvesicles from bone marrow mesenchymal stem cells in acute pancreatitis. Pancreas. 2016;45:1282–1293. doi: 10.1097/MPA.0000000000000694.
    1. Li T., Yan Y., Wang B., Qian H., Zhang X., Shen L., Wang M., Zhou Y., Zhu W., Li W., et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev. 2013;22:845–854. doi: 10.1089/scd.2012.0395.
    1. Qu Y., Zhang Q., Cai X., Li F., Ma Z., Xu M., Lu L. Exosomes derived from miR-181-5p-modified adipose-derived mesenchymal stem cells prevent liver fibrosis via autophagy activation. J. Cell. Mol. Med. 2017 doi: 10.1111/jcmm.13170.
    1. Tan C.Y., Lai R.C., Wong W., Dan Y.Y., Lim S.K., Ho H.K. Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. Stem Cell Res. Ther. 2014;5:76. doi: 10.1186/scrt465.
    1. Zhang B., Yin Y., Lai R.C., Tan S.S., Choo A.B., Lim S.K. Mesenchymal stem cells secrete immunologically active exosomes. Stem Cells Dev. 2014;23:1233–1244. doi: 10.1089/scd.2013.0479.
    1. Lee J.K., Park S.R., Jung B.K., Jeon Y.K., Lee Y.S., Kim M.K., Kim Y.G., Jang J.Y., Kim C.W. Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. PLoS ONE. 2013;8:e84256. doi: 10.1371/journal.pone.0084256.
    1. Ono M., Kosaka N., Tominaga N., Yoshioka Y., Takeshita F., Takahashi R.U., Yoshida M., Tsuda H., Tamura K., Ochiya T. Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci. Signal. 2014;7:ra63. doi: 10.1126/scisignal.2005231.
    1. Liu S., Liu D., Chen C., Hamamura K., Moshaverinia A., Yang R., Liu Y., Jin Y., Shi S. MSC transplantation improves osteopenia via epigenetic regulation of notch signaling in lupus. Cell Metab. 2015;22:606–618. doi: 10.1016/j.cmet.2015.08.018.
    1. Bai L., Shao H., Wang H., Zhang Z., Su C., Dong L., Yu B., Chen X., Li X., Zhang X. Effects of mesenchymal stem cell-derived exosomes on experimental autoimmune uveitis. Sci. Rep. 2017;7:4323. doi: 10.1038/s41598-017-04559-y.
    1. Cui X., He Z., Liang Z., Chen Z., Wang H., Zhang J. Exosomes from adipose-derived mesenchymal stem cells protect ischemic myocardium from ischemia/reperfusion injury via Wnt/[β]-catenin signaling pathway. J. Cardiovasc. Pharmacol. 2017 doi: 10.1097/FJC.0000000000000507.
    1. Long Q., Upadhya D., Hattiangady B., Kim D.-K., An S.Y., Shuai B., Prockop D.J., Shetty A.K. Intranasal MSC-derived A1-exosomes ease inflammation, and prevent abnormal neurogenesis and memory dysfunction after status epilepticus. Proc. Natl. Acad. Sci. USA. 2017;114:E3536–E3545. doi: 10.1073/pnas.1703920114.
    1. Zhu Y., Wang Y., Zhao B., Niu X., Hu B., Li Q., Zhang J., Ding J., Chen Y., Wang Y. Comparison of exosomes secreted by induced pluripotent stem cell-derived mesenchymal stem cells and synovial membrane-derived mesenchymal stem cells for the treatment of osteoarthritis. Stem Cell Res. Ther. 2017;8:64. doi: 10.1186/s13287-017-0510-9.
    1. Munoz J.L., Bliss S.A., Greco S.J., Ramkissoon S.H., Ligon K.L., Rameshwar P. Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol. Ther. Nucleic Acids. 2013;2:e126. doi: 10.1038/mtna.2013.60.
    1. Lou G., Song X., Yang F., Wu S., Wang J., Chen Z., Liu Y. Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma. J. Hematol. Oncol. 2015;8:122. doi: 10.1186/s13045-015-0220-7.
    1. Wu S., Ju G.Q., Du T., Zhu Y.J., Liu G.H. Microvesicles derived from human umbilical cord Wharton’s jelly mesenchymal stem cells attenuate bladder tumor cell growth in vitro and in vivo. PLoS ONE. 2013;8:e61366. doi: 10.1371/journal.pone.0061366.
    1. Bruno S., Collino F., Deregibus M.C., Grange C., Tetta C., Camussi G. Microvesicles derived from human bone marrow mesenchymal stem cells inhibit tumor growth. Stem Cells Dev. 2013;22:758–771. doi: 10.1089/scd.2012.0304.
    1. Fonsato V., Collino F., Herrera M.B., Cavallari C., Deregibus M.C., Cisterna B., Bruno S., Romagnoli R., Salizzoni M., Tetta C., et al. Human liver stem cell-derived microvesicles inhibit hepatoma growth in SCID mice by delivering antitumor microRNAs. Stem Cells. 2012;30:1985–1998. doi: 10.1002/stem.1161.
    1. Altanerova U., Benejova K., Altanerova V., Tyciakova S., Rychly B., Szomolanyi P., Ciampor F., Cihova M., Repiska V., Ondicova K., et al. Dental pulp mesenchymal stem/stromal cells labeled with iron sucrose release exosomes and cells applied intra-nasally migrate to intracerebral glioblastoma. Neoplasma. 2016;63:925–933. doi: 10.4149/neo_2016_611.
    1. Altaner C. Prodrug gene therapy for cancer mediated by mesenchymal stem/stromal cells engineered to express yeast cytosinedeaminase::Uracilphos phoribosyltransferase. J. Stem Cell Res. Ther. 2015;5:264.
    1. Santangelo L., Giurato G., Cicchini C., Montaldo C., Mancone C., Tarallo R., Battistelli C., Alonzi T., Weisz A., Tripodi M. The RNA-binding protein SYNCRIP is a component of the hepatocyte exosomal machinery controlling microRNA sorting. Cell. Rep. 2016;17:799–808. doi: 10.1016/j.celrep.2016.09.031.
    1. Didiot M.C., Hall L.M., Coles A.H., Haraszti R.A., Godinho B.M., Chase K., Sapp E., Ly S., Alterman J.F., Hassler M.R., et al. Exosome-mediated delivery of hydrophobically modified siRNA for huntingtin mRNA silencing. Mol. Ther. 2016;24:1836–1847. doi: 10.1038/mt.2016.126.
    1. Valadi H., Ekstrom K., Bossios A., Sjostrand M., Lee J.J., Lotvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007;9:654–659. doi: 10.1038/ncb1596.
    1. Stenqvist A.C., Nagaeva O., Baranov V., Mincheva-Nilsson L. Exosomes secreted by human placenta carry functional Fas ligand and TRAIL molecules and convey apoptosis in activated immune cells, suggesting exosome-mediated immune privilege of the fetus. J. Immunol. 2013;191:5515–5523. doi: 10.4049/jimmunol.1301885.
    1. Lai C.P., Mardini O., Ericsson M., Prabhakar S., Maguire C.A., Chen J.W., Tannous B.A., Breakefield X.O. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. ACS Nano. 2014;8:483–494. doi: 10.1021/nn404945r.
    1. Santangelo L., Battistelli C., Montaldo C., Citarella F., Strippoli R., Cicchini C. Functional roles and therapeutic applications of exosomes in hepatocellular carcinoma. Biomed. Res. Int. 2017;2017:2931813. doi: 10.1155/2017/2931813.
    1. Katsuda T., Tsuchiya R., Kosaka N., Yoshioka Y., Takagaki K., Oki K., Takeshita F., Sakai Y., Kuroda M., Ochiya T. Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes. Sci. Rep. 2013;3:1197. doi: 10.1038/srep01197.
    1. Lee M., Liu T., Im W., Kim M. Exosomes from adipose-derived stem cells ameliorate phenotype of Huntington’s disease in vitro model. Eur. J. Neurosci. 2016;44:2114–2119. doi: 10.1111/ejn.13275.
    1. Lopez-Verrilli M.A., Caviedes A., Cabrera A., Sandoval S., Wyneken U., Khoury M. Mesenchymal stem cell-derived exosomes from different sources selectively promote neuritic outgrowth. Neuroscience. 2016;320:129–139. doi: 10.1016/j.neuroscience.2016.01.061.
    1. Marote A., Teixeira F.G., Mendes-Pinheiro B., Salgado A.J. MSCS-derived exosomes: Cell-secreted nanovesicles with regenerative potential. Front. Pharmacol. 2016;7:231. doi: 10.3389/fphar.2016.00231.
    1. Fukuoka H., Suga H. Hair regeneration treatment using adipose-derived stem cell conditioned medium: Follow-up with trichograms. Eplasty. 2015;15:e10.
    1. Shin H., Ryu H.H., Kwon O., Park B.S., Jo S.J. Clinical use of conditioned media of adipose tissue-derived stem cells in female pattern hair loss: A retrospective case series study. Int. J. Dermatol. 2015;54:730–735. doi: 10.1111/ijd.12650.
    1. Katagiri W., Osugi M., Kawai T., Hibi H. First-in-human study and clinical case reports of the alveolar bone regeneration with the secretome from human mesenchymal stem cells. Head Face Med. 2016;12:5. doi: 10.1186/s13005-016-0101-5.
    1. Kordelas L., Rebmann V., Ludwig A.K., Radtke S., Ruesing J., Doeppner T.R., Epple M., Horn P.A., Beelen D.W., Giebel B. MSC-derived exosomes: A novel tool to treat therapy-refractory graft-versus-host disease. Leukemia. 2014;28:970–973. doi: 10.1038/leu.2014.41.
    1. Chen T.S., Arslan F., Yin Y., Tan S.S., Lai R.C., Choo A.B., Padmanabhan J., Lee C.N., de Kleijn D.P., Lim S.K. Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs. J. Transl. Med. 2011;9:47. doi: 10.1186/1479-5876-9-47.
    1. Ahluwalia A., Tarnawski A.S. Critical role of hypoxia sensor-HIF-1α in VEGF gene activation. Implications for angiogenesis and tissue injury healing. Curr. Med. Chem. 2012;19:90–97. doi: 10.2174/092986712803413944.
    1. Hawkins K.E., Sharp T.V., McKay T.R. The role of hypoxia in stem cell potency and differentiation. Regen. Med. 2013;8:771–782. doi: 10.2217/rme.13.71.
    1. Youn S.W., Lee S.W., Lee J., Jeong H.K., Suh J.W., Yoon C.H., Kang H.J., Kim H.Z., Koh G.Y., Oh B.H., et al. Comp-Ang1 stimulates HIF-1α-mediated SDF-1 overexpression and recovers ischemic injury through BM-derived progenitor cell recruitment. Blood. 2011;117:4376–4386. doi: 10.1182/blood-2010-07-295964.
    1. Haque N., Rahman M.T., Abu Kasim N.H., Alabsi A.M. Hypoxic culture conditions as a solution for mesenchymal stem cell based regenerative therapy. Sci. World J. 2013;2013:632972. doi: 10.1155/2013/632972.
    1. Estrada J.C., Albo C., Benguria A., Dopazo A., Lopez-Romero P., Carrera-Quintanar L., Roche E., Clemente E.P., Enriquez J.A., Bernad A., et al. Culture of human mesenchymal stem cells at low oxygen tension improves growth and genetic stability by activating glycolysis. Cell Death Differ. 2012;19:743–755. doi: 10.1038/cdd.2011.172.
    1. Fehrer C., Brunauer R., Laschober G., Unterluggauer H., Reitinger S., Kloss F., Gully C., Gassner R., Lepperdinger G. Reduced oxygen tension attenuates differentiation capacity of human mesenchymal stem cells and prolongs their lifespan. Aging Cell. 2007;6:745–757. doi: 10.1111/j.1474-9726.2007.00336.x.
    1. Pattappa G., Thorpe S.D., Jegard N.C., Heywood H.K., de Bruijn J.D., Lee D.A. Continuous and uninterrupted oxygen tension influences the colony formation and oxidative metabolism of human mesenchymal stem cells. Tissue Eng. Part C Methods. 2013;19:68–79. doi: 10.1089/ten.tec.2011.0734.
    1. D’Ippolito G., Diabira S., Howard G.A., Roos B.A., Schiller P.C. Low oxygen tension inhibits osteogenic differentiation and enhances stemness of human miami cells. Bone. 2006;39:513–522. doi: 10.1016/j.bone.2006.02.061.
    1. Yamamoto Y., Fujita M., Tanaka Y., Kojima I., Kanatani Y., Ishihara M., Tachibana S. Low oxygen tension enhances proliferation and maintains stemness of adipose tissue-derived stromal cells. Biores. Open Access. 2013;2:199–205. doi: 10.1089/biores.2013.0004.
    1. Liu L., Gao J., Yuan Y., Chang Q., Liao Y., Lu F. Hypoxia preconditioned human adipose derived mesenchymal stem cells enhance angiogenic potential via secretion of increased VEGF and BFGF. Cell Biol. Int. 2013;37:551–560. doi: 10.1002/cbin.10097.
    1. Ahmed N.E., Murakami M., Kaneko S., Nakashima M. The effects of hypoxia on the stemness properties of human dental pulp stem cells (DPSCs) Sci. Rep. 2016;6:35476. doi: 10.1038/srep35476.
    1. Lee S.C., Jeong H.J., Lee S.K., Kim S.J. Hypoxic conditioned medium from human adipose-derived stem cells promotes mouse liver regeneration through JAK/STAT3 signaling. Stem Cells Transl. Med. 2016;5:816–825. doi: 10.5966/sctm.2015-0191.
    1. Yu J., Yin S., Zhang W., Gao F., Liu Y., Chen Z., Zhang M., He J., Zheng S. Hypoxia preconditioned bone marrow mesenchymal stem cells promote liver regeneration in a rat massive hepatectomy model. Stem Cell Res. Ther. 2013;4:83. doi: 10.1186/scrt234.
    1. Croitoru-Lamoury J., Lamoury F.M., Caristo M., Suzuki K., Walker D., Takikawa O., Taylor R., Brew B.J. Interferon-γ regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO) PLoS ONE. 2011;6:e14698. doi: 10.1371/journal.pone.0014698.
    1. Kang J.W., Koo H.C., Hwang S.Y., Kang S.K., Ra J.C., Lee M.H., Park Y.H. Immunomodulatory effects of human amniotic membrane-derived mesenchymal stem cells. J. Vet. Sci. 2012;13:23–31. doi: 10.4142/jvs.2012.13.1.23.
    1. Lin W., Oh S.K., Choo A.B., George A.J. Activated T cells modulate immunosuppression by embryonic-and bone marrow-derived mesenchymal stromal cells through a feedback mechanism. Cytotherapy. 2012;14:274–284. doi: 10.3109/14653249.2011.635853.
    1. Kwon Y.W., Heo S.C., Jeong G.O., Yoon J.W., Mo W.M., Lee M.J., Jang I.H., Kwon S.M., Lee J.S., Kim J.H. Tumor necrosis factor-α-activated mesenchymal stem cells promote endothelial progenitor cell homing and angiogenesis. Biochim. Biophys. Acta. 2013;1832:2136–2144. doi: 10.1016/j.bbadis.2013.08.002.
    1. Lu Z., Wang G., Dunstan C.R., Chen Y., Lu W.Y., Davies B., Zreiqat H. Activation and promotion of adipose stem cells by tumour necrosis factor-α preconditioning for bone regeneration. J. Cell Physiol. 2013;228:1737–1744. doi: 10.1002/jcp.24330.
    1. Grote K., Petri M., Liu C., Jehn P., Spalthoff S., Kokemuller H., Luchtefeld M., Tschernig T., Krettek C., Haasper C., et al. Toll-like receptor 2/6-dependent stimulation of mesenchymal stem cells promotes angiogenesis by paracrine factors. Eur. Cell Mater. 2013;26:66–79. doi: 10.22203/eCM.v026a05.
    1. Cho Y.J., Song H.S., Bhang S., Lee S., Kang B.G., Lee J.C., An J., Cha C.I., Nam D.H., Kim B.S., et al. Therapeutic effects of human adipose stem cell-conditioned medium on stroke. J. Neurosci. Res. 2012;90:1794–1802. doi: 10.1002/jnr.23063.
    1. Ma T., Grayson W.L., Frohlich M., Vunjak-Novakovic G. Hypoxia and stem cell-based engineering of mesenchymal tissues. Biotechnol. Prog. 2009;25:32–42. doi: 10.1002/btpr.128.
    1. Bartosh T.J., Ylostalo J.H., Mohammadipoor A., Bazhanov N., Coble K., Claypool K., Lee R.H., Choi H., Prockop D.J. Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties. Proc. Natl. Acad. Sci. USA. 2010;107:13724–13729. doi: 10.1073/pnas.1008117107.
    1. Frith J.E., Thomson B., Genever P.G. Dynamic three-dimensional culture methods enhance mesenchymal stem cell properties and increase therapeutic potential. Tissue Eng. Part C Methods. 2010;16:735–749. doi: 10.1089/ten.tec.2009.0432.
    1. Ranganath S.H., Tong Z., Levy O., Martyn K., Karp J.M., Inamdar M.S. Controlled inhibition of the mesenchymal stromal cell pro-inflammatory secretome via microparticle engineerifng. Stem Cell Rep. 2016;6:926–939. doi: 10.1016/j.stemcr.2016.05.003.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa